Arrowstreet Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,127,162	Closed	-$448M	–	1824
2025 Q4	$448M	Sell	1,127,162 -228,447	-17%	-$101M	0.26%	86
2025 Q3	$618M	Buy	1,355,609 +1,185,909	+699%	+$483M	0.39%	57
2025 Q2	$55.3M	Buy	169,700 +165,645	+4,085%	+$45.8M	0.04%	395
2025 Q1	$1.09M	Buy	+4,055	New	+$1.04M	﹤0.01%	1455
2024 Q3	–	Sell	-14,971	Closed	-$3.64M	–	1721
2024 Q2	$3.64M	Buy	+14,971	New	+$2.36M	﹤0.01%	930
2021 Q1	–	Sell	-61,300	Closed	-$7.97M	–	2214
2020 Q4	$7.97M	Buy	61,300 +57,583	+1,549%	+$7.69M	0.01%	980
2020 Q3	$541K	Buy	3,717 +1,517	+69%	+$216K	﹤0.01%	1996
2020 Q2	$326K	Buy	+2,200	New	+$297K	﹤0.01%	2084
2020 Q1	–	Sell	-3,300	Closed	-$380K	–	1844
2019 Q4	$380K	Buy	+3,300	New	+$329K	﹤0.01%	1534
2017 Q4	–	Sell	-51,485	Closed	-$6.05M	–	1227
2017 Q3	$6.05M	Buy	+51,485	New	+$4.39M	0.02%	468
2015 Q3	–	Sell	-13,274	Closed	-$1.59M	–	1333
2015 Q2	$1.59M	Buy	+13,274	New	+$1.59M	0.01%	694
2014 Q2	–	Sell	-43,081	Closed	-$2.89M	–	955
2014 Q1	$2.89M	Buy	+43,081	New	+$3.34M	0.02%	568